🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

123 results for “Sanofi” Clear

  1. -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

    Sanofi Pharma Bristol-Myers Squibb

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  2. -, TACROLIMUS , Amlitelimab, PIMECROLIMUS , Placebo, Amlitelimab

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  3. A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 other active

    1 trial

  4. AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

    Sanofi Pharma Bristol-Myers Squibb

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  5. AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  6. Amlitelimab, Amlitelimab, -, -, -, Amlitelimab

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  7. Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  8. Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

    Sanofi Pharma Bristol-Myers Squibb

    atopic dermatitis

    phase 3 small molecule active

    1 trial

  9. Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection

    Sanofi Pharma Bristol-Myers Squibb

    Thrombotic Thrombocytopenic Purpura

    phase 3 small molecule active

    1 trial

  10. Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671

    Sanofi Pharma Bristol-Myers Squibb

    Gaucher's disease type III

    phase 3 small molecule active

    1 trial

  11. Dupilumab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  12. Dupilumab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  13. Duvakitug, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 small molecule active

    1 trial

  14. Duvakitug, matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 small molecule active

    1 trial

  15. FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

    Sanofi Pharma Bristol-Myers Squibb

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  16. Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

    Sanofi Pharma Bristol-Myers Squibb

    Fabry’s disease

    phase 3 small molecule active

    1 trial

  17. Frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  18. Imnovid 3 mg hard capsules, Isatuximab, Dexamethason 4 mg JENAPHARM®, JAMP Pomalidomide, JAMP Pomalidomide, Isatuximab, Imnovid 4 mg hard capsules, JAMP Pomalidomide, MONTELUKAST , Pomalidomide Adalvo 4 mg hard capsules, JAMP Pomalidomide, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Imnovid 1 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, DEXAMETHASONE, Imnovid 1 mg hard capsules, Isatuximab, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Dexamethason

    Sanofi Pharma Bristol-Myers Squibb

    Cancer - Plasma cell myeloma recurrent

    phase 3 small molecule active

    1 trial

  19. Itepekimab, Matched Placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  20. Itepekimab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  21. Itepekimab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  22. LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test

    Sanofi Pharma Bristol-Myers Squibb

    Pruritus

    phase 3 small molecule active

    1 trial

  23. Live Attenuated Respiratory Syncytial Virus (RSV) ∆NS2/∆1313/I1314L vaccine, Matched

    Sanofi Pharma Bristol-Myers Squibb

    Virus diseases

    phase 3 small molecule active

    1 trial

  24. Matched placebo for product, Frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    Multiple sclerosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources